Pharma in China
Linked bleow is a market report discussing the market opportunities for pharma in China. They are not-surprisingly huge.
[May require registration with Nature to access, but free]
But factors work against a huge pharma opportunity as well. Still largely rural population (but urbanizing), still poor (but getting wealthier), and a majority patient pay system.
Watch that last one closely. If China adopts a US based or even better European based system, then the pharma opportunity is really huge. [Note that a US system might be better long run, but a European would mean more rapid initial market growth IMO].
Looking from a different side, I think the current demographic / payee system favors nicely nutraceuticals, and companies such as AOB. Recent bullish call on this one in my CAPS port.